Experimental cancer drug trial halted early
NCT ID NCT02712905
First seen Nov 04, 2025 · Last updated May 01, 2026 · Updated 24 times
Summary
This early-stage trial tested an experimental drug called INCB059872 in 116 people with advanced solid tumors or blood cancers that had stopped responding to standard treatments. The study aimed to find a safe dose and check for side effects, both when the drug was given alone and with other cancer medicines. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS AND HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University
New York, New York, 10027, United States
-
Erasmus MC
Rotterdam, Netherlands
-
Institut Jules Bordet
Brussels, Belgium
-
Moores UCSD Cancer Center
La Jolla, California, 92093, United States
-
Netherland Cancer Institute
Amsterdam, Netherlands
-
Northwestern University
Chicago, Illinois, 60208, United States
-
Oregon Health Science University
Portland, Oregon, 97297, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
University of Alabama
Birmingham, Alabama, 35487, United States
-
University of Kansas Center for Research, Inc.
Kansas City, Kansas, 66045, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
VU Medical Center
Amsterdam, Netherlands
-
Vanderbilt University
Nashville, Tennessee, 37240, United States
Conditions
Explore the condition pages connected to this study.